Compare LAES & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | TRDA |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.0M | 386.8M |
| IPO Year | N/A | 2021 |
| Metric | LAES | TRDA |
|---|---|---|
| Price | $4.02 | $11.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 14.4M | 242.4K |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,978,000.00 | ★ $61,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.48 | $4.93 |
| 52 Week High | $11.00 | $19.93 |
| Indicator | LAES | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 73.90 |
| Support Level | $4.45 | $10.40 |
| Resistance Level | $5.09 | $11.24 |
| Average True Range (ATR) | 0.38 | 0.54 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 10.81 | 86.96 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.